MCL Literature Feed

Fixed-duration glofitamab monotherapy achieves high complete response rates (78%) in heavily pretreated relapsed/refractory MCL, including post-BTKi patients, offering a potent new off-the-shelf immunotherapy.

This case report details the management of severe brexu-cel toxicities, including a rare intestinal perforation, and highlights the use of anakinra for ICANS, emphasizing complex toxicity management.

Rituximab maintenance after bendamustine-based therapy in MCL patients is associated with worse outcomes from SARS-CoV-2 infection, highlighting a significant infectious toxicity risk for this common regimen.

This case report of late, recurrent neurotoxicity after brexucabtagene autoleucel demonstrates a mechanism of direct CNS infiltration by CAR-T cells, highlighting the need for long-term vigilance.

Pirtobrutinib achieves an 81% overall response rate in MCL patients intolerant to prior covalent BTKis, offering a well-tolerated sequential option to maintain effective BTK pathway inhibition.

A novel electrochemical sensor was developed for highly sensitive bortezomib detection, potentially enabling therapeutic drug monitoring to personalize dosing and manage toxicity in MCL patients.

This first-in-literature case report identifies sclerosing cholangitis as a novel, severe hepatobiliary toxicity of Tecartus CAR-T therapy in a relapsed/refractory MCL patient, expanding the known safety profile.

This case report highlights the critical role of MRI in diagnosing post-CAR-T neurotoxicity in MCL, demonstrating findings like limbic encephalitis to differentiate ICANS from other CNS pathologies.

This meta-analysis of tirabrutinib monotherapy in relapsed/refractory B-cell lymphomas, including MCL, shows a pooled 72.5% overall response rate with manageable neutropenia and skin-related toxicities.

This case report details persistent cytokine release syndrome in an MCL patient after glofitamab, highlighting a rare, severe toxicity profile requiring vigilant management beyond standard CRS protocols.

This case report demonstrates that MCL can rarely cause membranous nephropathy, a severe renal complication that can be fully resolved by successfully treating the underlying lymphoma with chemotherapy.

This preclinical rat study shows the antifungal posaconazole increases zanubrutinib plasma exposure, highlighting a significant drug-drug interaction that may necessitate dose adjustments in MCL patients to avoid toxicity.

This retrospective study suggests a 1-day bendamustine regimen for MCL offers comparable progression-free survival to the standard 2-day schedule but with significantly less neutropenia and adverse events.

A case of ganciclovir-resistant CMV encephalitis in a pirtobrutinib-treated MCL patient highlights a rare but severe infectious complication, urging vigilance for CNS symptoms with this non-covalent BTKi.

This preclinical study explains bortezomib-induced pulmonary toxicity, showing it increases endothelial RhoA/RhoC proteins, which synergize with inflammation to cause vascular hyperpermeability and capillary leak syndrome.

This general review contextualizes CAR T-cell therapy, including its approved use in mantle cell lymphoma, within the broader landscape of cellular therapies, summarizing its efficacy and common toxicities.

This review details Bortezomib's multiple anti-cancer mechanisms and significant toxicities, highlighting the need for next-generation proteasome inhibitors with better therapeutic windows for treating mantle cell lymphoma.

This review summarizes the established efficacy and toxicities of CD19 CAR-T therapy in B-cell lymphomas, including MCL, while highlighting future research directions like novel targets and sequencing with bispecifics.

This retrospective case series strengthens the link between ibrutinib and delayed-onset uveitis, a potentially vision-threatening toxicity that resolves upon drug cessation, highlighting a key clinical management consideration.

This phase 1 trial establishes the safety and preliminary efficacy of combining the HDAC inhibitor abexinostat with ibrutinib in relapsed/refractory MCL, suggesting a potential new BTKi-based combination strategy.

This first case report of concurrent zanubrutinib and radiotherapy demonstrates a manageable safety profile, suggesting BTKi therapy may not require interruption for necessary radiation in MCL patients.

Long-term follow-up after autologous stem cell transplant in MCL is critical for detecting late relapses and managing treatment-related toxicities, guiding post-transplant surveillance strategies.

Bendamustine-induced lymphopenia in frontline MCL resolves by 12 months, suggesting a minimum 9-month wait before leukapheresis for CAR-T therapy to ensure sufficient lymphocyte collection.

In a small retrospective study of nine untreated aggressive MCL patients, adding a BTKi to chemoimmunotherapy achieved a 100% objective response rate with manageable toxicity, suggesting a promising frontline strategy.

The KRD regimen (carfilzomib, lenalidomide, dexamethasone) is highly toxic and ineffective for BTKi-relapsed/refractory MCL, with only 13% 12-month OS, establishing this is not a viable salvage therapy.

A validated LC-MS/MS assay simultaneously measures plasma ibrutinib, its active metabolite, and zanubrutinib, enabling therapeutic drug monitoring to potentially optimize dosing and manage toxicity in MCL.

This case of cardiac MCL with a mobile tumor highlights the risk of fatal pulmonary embolism post-chemotherapy, suggesting a potential role for pre-treatment surgical intervention in this rare presentation.

The frontline, chemotherapy-free triplet of acalabrutinib, venetoclax, and rituximab achieved 100% ORR and high MRD negativity, establishing a potent, time-limited option despite significant COVID-19 toxicity.

This review explores CAR-NK cells as a promising alternative to CAR-T therapy for mantle cell lymphoma, potentially offering comparable efficacy with a significantly improved safety profile and fewer severe toxicities.

A meta-analysis of 7,604 patients found mantle cell lymphoma has the highest non-relapse mortality (10.6%) post-CAR-T, with infections being the primary cause, not CAR-T-specific toxicities.